The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study
Open accessAbstract
Objective: The introduction of anti tumour necrosis factor-α (anti-TNFα) therapy might impact healthcare expenditures, but there are limited data regarding the costs of inflammatory bowel diseases (IBD) following the introduction of these drugs. We aimed to assess the healthcare costs and productivity losses in a large cohort of IBD patients. Design: Crohn's disease (CD) and ulcerative colitis (UC) patients from seven university hospitals and seven general hospitals were invited to fill-out a web-based questionnaire. Cost items were derived from a 3 month follow-up questionnaire and categorised in outpatient clinic, diagnostics, medication, surgery and hospitalisation. Productivity losses included sick leave of paid and unpaid work. Costs were expressed as mean 3-month costs per patients with a 95% CI obtained using non-parametric bootstrapping. Results: A total of 1315 CD patients and 937 UC patients were included. Healthcare costs were almost three times higher in CD as compared with UC, €1625 (95% CI €1476 to €1775) versus €595 (95% CI €505 to €685), respectively (p<0.01). Anti-TNFα use was the main costs driver, accounting for 64% and 31% of the total cost in CD and UC. Hospitalisation and surgery together accounted for 19% and <1% of the healthcare costs in CD and 23% and 1% in UC, respectively. Productivity losses accounted for 16% and 39% of the total costs in CD and UC. Conclusions: We showed that healthcare costs are mainly driven by medication costs, most importantly by anti-TNFα therapy. Hospitalisation and surgery accounted only for a minor part of the healthcare costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Long-Term Evolution of Disease Behavior of Crohn's Disease
Cosnes, J., Cattan, S., Blain, A., Beaugerie, L., Carbonnel, F., Parc, R., & Gendre, J.-P. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200207000-00002 · Cited by 1,346
The Epidemiology of Inflammatory Bowel Disease in Canada: A Population-Based Study
Bernstein, C. N., Wajda, A., Svenson, L. W., MacKenzie, A., Koehoorn, M., Jackson, M., Fedorak, R., Israel, D., & Blanchard, J. F. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00603.x · Cited by 636
Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults
Kappelman, M. D., Rifas–Shiman, S. L., Porter, C. Q., Ollendorf, D. A., Sandler, R. S., Galanko, J. A., & Finkelstein, J. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.012 · Cited by 634
Feagan, B. G., Panaccione, R., Sandborn, W. J., D'Haens, G. R., Schreiber, S., Rutgeerts, P. J., Loftus, E. V., Lomax, K. G., Yu, A. P., Wu, E. Q., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.069 · Cited by 374
Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study
Bassi, A., Dodd, S., Williamson, P., & Bodger, K. (2004) · Gut · doi:10.1136/gut.2004.041616 · Cited by 309
Hospitalisations and surgery in Crohn's disease
Bernstein, C. N., Loftus, E. V., Ng, S. C., Lakatos, P. L., & Moum, B. (2012) · Gut · doi:10.1136/gutjnl-2011-301397 · Cited by 294
The Epidemiology of Colectomy in Ulcerative Colitis: Results From a Population-Based Cohort
Targownik, L. E., Singh, H., Nugent, Z., & Bernstein, C. N. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.127 · Cited by 280
High incidence of Crohnʼs disease in Canterbury, New Zealand: Results of an epidemiologic study
Gearry, R. B., Richardson, A., Frampton, C. M. A., Collett, J. A., Burt, M. J., Chapman, B. A., & Barclay, M. L. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000231572.88806.b9 · Cited by 273
Lichtenstein, G. R., Yan, S., Bala, M., & Hanauer, S. (2004) · American Journal of Gastroenterology · doi:10.1046/j.1572-0241.2003.04010.x · Cited by 265
Molinié, F., Gower-Rousseau, C., Yzet, T., Merle, V, Grandbastien, B., Marti, R., Lerebours, E., Dupas, J.-L., Colombel, J.-F., Salomez, J.-L., et al. (2004) · Gut · doi:10.1136/gut.2003.025346 · Cited by 255
Research works printed but not linked: 4
- 10.1136/ard.2005.039420 · doi:10.1136/ard.2005.039420
- 10.1002/art.10998 · doi:10.1002/art.10998
- 10.1136/ard.2005.047175 · doi:10.1136/ard.2005.047175
- Cosnes, 2008, Crohn's disease phenotype, prognosis, and long-term complications: what to expect, Acta Gastroenterol Belg, 71, 303
Cited by
The burden of inflammatory bowel disease in Europe
Burisch, J., Jess, T., Martinato, M., & Lakatos, P. L. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2013.01.010 · Cited by 961
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Vande Casteele, N., Ferrante, M., Van Assche, G., Ballet, V., Compernolle, G., Van Steen, K., Simoens, S., Rutgeerts, P., Gils, A., & Vermeire, S. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.031 · Cited by 886
Shivashankar, R., Tremaine, W. J., Harmsen, W. S., & Loftus, E. V. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.10.039 · Cited by 455
The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation
Park, K. T., Ehrlich, O. G., Allen, J. I., Meadows, P., Szigethy, E. M., Henrichsen, K., Kim, S. C., Lawton, R. C., Murphy, S. M., Regueiro, M., et al. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz104 · Cited by 431
The Burden of Inflammatory Bowel Disease in Europe in 2020
Zhao, M., Gönczi, L., Lakatos, P. L., & Burisch, J. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab029 · Cited by 426
Metadata
- Authors
- van der Valk, M. E., Mangen, M.-J. J., Leenders, M., Dijkstra, G., van Bodegraven, A. A., Fidder, H. H., de Jong, D. J., Pierik, M., van der Woude, C. J., Romberg-Camps, M. J. L., Clemens, C. H., Jansen, J. M., Mahmmod, N., van de Meeberg, P. C., van der Meulen-de Jong, A. E., Ponsioen, C. Y., Bolwerk, C. J., Vermeijden, J. R., Siersema, P. D., van Oijen, M. G., Oldenburg, B., & on behalf of the COIN study group and the Dutch Initiative on Crohn and Colitis
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2012-11-07
- Volume
- 63
- Issue
- 1
- Pages
- 72-79
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2169467558
- Cited by
- 500
- References
- 26
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. https://app.cochat.ai/papers/10.1136/gutjnl-2012-303376
- The paper
- van der Valk, M. E., Mangen, M.-J. J., Leenders, M., Dijkstra, G., van Bodegraven, A. A., Fidder, H. H., de Jong, D. J., Pierik, M., van der Woude, C. J., Romberg-Camps, M. J. L., Clemens, C. H., Jansen, J. M., Mahmmod, N., van de Meeberg, P. C., van der Meulen-de Jong, A. E., Ponsioen, C. Y., Bolwerk, C. J., Vermeijden, J. R., Siersema, P. D., . . . on behalf of the COIN study group and the Dutch Initiative on Crohn and Colitis. (2014). Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. https://doi.org/10.1136/gutjnl-2012-303376
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.